Join Growin Stock Community!
Back to PFE.US Analysis
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

operation-income-chart

PFE Operation Income

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

As of Q4'25, Pfizer's latest reported operating income stands at $3.69B USD, marking a significant recovery from the previous quarters. The year-over-year (YoY) growth rate for this period is exceptionally high at 369.8%, indicating a substantial improvement compared to the same quarter last year. Over the period from Q1'23 to Q4'25, Pfizer's operating income exhibited considerable volatility, with notable losses in Q3'23 (-$3.35B USD) and Q4'23 (-$4.13B USD), followed by a return to profitability in 2024 and a strong upward trend through 2025. The YoY growth rates reflect this volatility, with deep negative values throughout 2023 and early 2024, before surging to positive territory in late 2024 and peaking dramatically in 2025. This pattern suggests a period of operational challenges followed by a robust turnaround and accelerated growth in the most recent quarters.